Pyrrolopyrimidine compound as BTK inhibitor and use thereof
Disclosed are a pyrrolopyrimidine compound and a use thereof in preparing a medicine for diseases related to a BTK protein kinase inhibitor. Specially, disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
1. A compound represented by formula (III) or a pharmaceutically acceptable salt thereof,
wherein,
R 1 is C 1-3 alkoxy, wherein the C 1-3 alkoxy is optionally substituted by 1, 2, or 3 R a ;
each R a is selected from the group consisting of D, halogen, and OH;
R 2 is selected from the group consisting of halogen, methyl, phenoxy, and pyridyloxy, wherein the phenoxy and pyridyloxy are optionally substituted with 1, 2 or 3 halogens;
R 3 is -CH 2 OH
m is 1 or 2;
n is 1, 2, or 3;
E 1 is selected from the group consisting of O, S and NH; and
ring A is
2. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein each Ra is selected from the group consisting of D, F, and OH.
3. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 1 is selected from the group consisting of OCH 3 , OCD 3 , and OCH 2 CH 2 OH.
4. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein R 2 is selected from the group consisting of F, Cl, methyl, phenoxy, 2-fluorophenoxy, and 2-pyridyloxy.
5. The compound or pharmaceutically acceptable salt thereof according to claim 1 , wherein E 1 is NH.
6. The compound or pharmaceutically acceptable salt thereof according to claim 1 , which is
wherein R 1 , R 2 and m are as defined in claim 1 .
7. A compound represented by the following formula or a pharmaceutically acceptable salt thereof, which is selected from the group consisting of:
8. The compound or pharmaceutically acceptable salt thereof according to claim 7 , which is selected from the group consisting of:
9. A method of treating a lymphoma in a subject in need thereof, comprising administering to the subject the compound or pharmaceutically acceptable salt thereof according to claim 1 .
10. A method of treating a lymphoma in a subject in need thereof, comprising administering to the subject the compound or pharmaceutically acceptable salt thereof according to claim 7 .
11. A method of treating a lymphoma in a subject in need thereof, comprising administering to the subject the compound or pharmaceutically acceptable salt thereof according to claim 8 .